This is supported by the finding that pharmacological phosphorylation of p53 leads to the decreased expression of PINK1 in SH-SY5Y neuroblastoma cells and inhibition of p53 activity increases both PINK1 protein expression and mRNA levels in the cell treated with pifithrin-α (PFT), a well-known p53 inhibitor. This evidence concerns the gene PINK1 and neuroblastoma.